Table 1.
Clinical, demographic, and laboratory characteristics of patients and healthy subjects
| ACS | Healthy | P-value | |
|---|---|---|---|
| Age (years) | 58.9 ± 2.3 | 58.7 ± 2.3 | n.s. |
| Male gender (%) | 15 (94) | 10 (63) | n.s |
| Caucasian ethnicity (%) | 16 (100) | 16 (100) | n.s. |
| Leucocyte count (103/µL) | 11.6 ± 1.5 | 5.8 ± 0.3 | P ≤ 0.001 |
| Lymphocyte count (103/µL) | 3.2 ± 1.2 | 1.6 ± 0.08 | n.s. |
| Erythrocytes (106/µL) | 4.3 ± 0.2 | 4.5 ± 0.1 | n.s. |
| Platelets (103/µL) | 279 ± 25 | 219 ± 8 | P < 0.05 |
| Total cholesterol (mmol/L) | 5.1 ± 0.4 | 5.6 ± 0.3 | n.s. |
| Baseline glucose (mmol/L) | 9.0 ± 1.7 | 5.2 ± 0.08 | P ≤ 0.01 |
| Serum creatinine (µmol/L) | 79.9 ± 6.3 | 72.1 ± 2.7 | n.s. |
| eGFR (mL/min) | 90.1 ± 4.9 | 92.3 ± 2.4 | n.s. |
| BMI (kg/m2) | 28.4 ± 2.0 | 24.6 ± 1.1 | n.s. |
| Gensini Score | 39.7 ± 5.7 | 0 | P ≤ 0.001 |
| Cardiovascular risk factors | |||
| Hypercholesterolaemia | 8 (50) | 0 | P ≤ 0.01 |
| Hypertension (%) | 4 (25) | 0 | P < 0.05 |
| Diabetes (%) | 2 (13) | 0 | n.s. |
| Smoking (current, %) | 7 (44) | 0 | P ≤ 0.01 |
| Previous medical history | |||
| Previous MI | 3 (19) | 0 | n.s. |
| Previous PCI | 2 (13) | 0 | n.s. |
| Medications | |||
| Aspirin (%) | 16 (100) | 0 | P ≤ 0.001 |
| Statins (%) | 4 (25) | 0 | P < 0.05 |
| ACE-I/ARB (%) | 2 (13) | 0 | n.s. |
| β-Blockers (%) | 3 (19) | 0 | n.s. |
| Nitrates (%) | 15 (94) | 0 | P ≤ 0.001 |
| Calcium antagonists (%) | 0 | 0 | – |
| Diuretics (%) | 1 (6) | 0 | n.s. |
Values are shown as mean ± SEM or absolute and relative frequencies (in brackets with respect to n = 16 patients), respectively.
N = 12–16; n.s. non-significant. ACE-I/ARB, angiotensin converting enzyme-inhibitor/angiotensin receptor blocker; aspirin comprises oral and intravenous formulation; BMI, body mass index; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention.